531541 — KOBO Biotech Income Statement
0.000.00%
Last trade - 00:00
- IN₹96.97m
- IN₹1.49bn
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0 | 0 | 0 | 0 | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 113 | 84.9 | 78.4 | 151 | 55.7 |
Operating Profit | -113 | -84.9 | -78.4 | -151 | -55.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -245 | -210 | -192 | -152 | -55.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -245 | -210 | -192 | -152 | -55.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -245 | -210 | -192 | -152 | -55.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -245 | -210 | -192 | -152 | -55.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -9.35 | -8.82 | -8.07 | -6.39 | -2.33 |